2022 World Conference on Lung Cancer (Posters)-P2.10-02. EMERGE 402: Preliminary Real-world Characteristics and Safety of Lurbinectedin in Patients With Small-cell Lung Cancer

Pdf Summary

The EMERGE 402 trial is evaluating the real-world use and safety of lurbinectedin, a therapy for small-cell lung cancer (SCLC) that has received accelerated approval in the US and conditional approval in Canada. The trial aims to enroll approximately 300 patients who previously received platinum-based chemotherapy for SCLC. Preliminary analysis of the trial revealed that lurbinectedin was administered as second-line therapy for 40% of patients and as third- or later-line therapy for 60% of patients. The majority of patients had received prior immunotherapy in addition to platinum-based chemotherapy. The real-world safety profile of lurbinectedin was generally consistent with the results of a phase 2 trial, with no new safety signals identified.<br /><br />The trial is still ongoing and continues to enroll patients to further assess the effectiveness and safety of lurbinectedin monotherapy. The baseline characteristics of the enrolled patients showed a diverse population, with 26% of patients having central nervous system involvement and 79% of patients having received prior immunotherapy. The trial is collecting data on patient demographics, response assessment, survival status, patterns of lurbinectedin utilization, safety and tolerability, and health-related quality of life.<br /><br />The analysis also provided a summary of the treatment patterns among the patients receiving lurbinectedin. All patients received prior platinum-based chemotherapy, and 60% of patients received first-line triplet therapy that included anti-PDL1 immunotherapy. Among patients who received lurbinectedin as second-line therapy, the majority had received first-line platinum-based chemotherapy plus immunotherapy. Conversely, most patients who were rechallenged with platinum-based chemotherapy in the second-line setting had previously received first-line platinum doublet alone.<br /><br />Overall, the preliminary analysis of the EMERGE 402 trial suggests that lurbinectedin is being used in a real-world setting for patients with previously treated SCLC. The safety profile and treatment patterns observed are consistent with clinical trial findings. The trial will provide more comprehensive data on the effectiveness and safety of lurbinectedin monotherapy in a broader SCLC population.

Asset Subtitle

Balazs Halmos, United States

Meta Tag

Speaker Balazs Halmos, United States

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours

Keywords

EMERGE 402 trial

lurbinectedin

small-cell lung cancer

accelerated approval

conditional approval

platinum-based chemotherapy

immunotherapy

safety profile

effectiveness

real-world setting